Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 19.69, indicating strong short-term liquidity coverage relative to liabilities. Total assets stand at $6.44 million against total liabilities of $0.31 million, resulting in total equity of $6.11 million. The company trades at a price-to-book ratio of 0.82, reflecting a market capitalization of $4.70 million that is below its book value. Despite the strong balance sheet ratios, the company faces a high risk of delisting as the share price dropped below the $1.00 minimum bid threshold to $0.9076 in July 2026, triggering a continued-listing deficiency alert.

The company is not yet profitable, reporting a net loss of $1.41 million and an operating loss of $1.46 million for the first quarter of 2026. Return on equity is -98.12% and return on assets is -93.08%, indicating significant erosion of shareholder value through accumulated deficits. Operating cash flow was negative $1.32 million, driven by the net loss and changes in working capital, while investing activities consumed an additional $175,000 for note receivables and related entity investments. The company has no revenue, resulting in undefined profitability margins and a complete reliance on external capital to sustain operations.

Revenue concentration is not applicable as the company reported $0.0 in revenue for the period. The business model appears focused on intellectual property development and licensing, as evidenced by amortization of intangible assets and patent-related disclosures in the financial statements. There is no geographic or segment revenue mix to analyze, suggesting the company is in a pre-commercialization or early-stage development phase.

Growth trajectory is characterized by a lack of top-line expansion, with revenue remaining at zero. However, the company has actively raised capital to fund its operations, including a registered direct offering in October 2024 that sold 418,552 shares at $4.42 per share, generating net proceeds of approximately $1.6 million. In the first quarter of 2025, the company raised $3.36 million from the sale of common stock and warrants. Share count increased from 1.75 million in December 2024 to 3.70 million by March 2026, reflecting significant dilution from these financing events.

Key risks include medium dilution risk due to the history of equity offerings and warrant exercises, as well as low liquidity risk in terms of balance sheet strength but high market liquidity risk due to the sub-$1.00 share price. The company faces continued-listing threats on Nasdaq due to the price deficiency, which could limit investor access and increase volatility. Additionally, the company’s future success depends on its ability to adapt to technological advances and develop new products, as noted in its risk factors.

Recent events include the filing of unaudited condensed consolidated statements for Q1 2026, which detail the cash burn and financing activities. The company also disclosed a patent purchase agreement requiring a $100,000 initial payment, highlighting ongoing capital commitments for intellectual property acquisition. Analyst estimates show a mean price target of $20.00, which is significantly higher than the current market price, suggesting potential upside if the company achieves its development milestones, though this is based on limited analyst coverage with only one buy rating.

Creative Medical Technology Holdings, Inc. (CELZ) has undergone a comprehensive revision of its AI-driven analytical profile, with significant updates to its business summary, narrative, and key takeaways. These modifications, sourced from the ha_light_thesis, indicate a substantial shift in the underlying assessment of the company's operational and strategic positioning. The revision of the conclusion and key takeaways suggests that recent developments or data inputs have necessitated a re-evaluation of the firm's prospects, altering the previous analytical consensus. The most notable quantitative adjustment in this update is a 9.9% decrease in the company's estimated market share, which fell from approximately 4.11e-11 to 3.70e-11. While the absolute figures remain infinitesimally small, the relative decline highlights a contraction in the company's perceived footprint within its sector. This metric change, coupled with the qualitative revisions, underscores a nuanced but distinct downward adjustment in the analytical model's view of CELZ's competitive standing. Despite these analytical shifts, the fundamental structural profile of Creative Medical Technology remains unchanged. The company continues to operate with a single officer and maintains a top holder count of six, indicating a concentrated ownership structure. Furthermore, the absence of analyst coverage and index membership persists, reflecting the firm's status as a niche entity with limited institutional visibility and professional research attention. The significance of these changes lies in the divergence between the static corporate structure and the dynamic analytical assessment. With no new material events or cross-source signals reported, the revisions appear driven by internal model recalibrations rather than external corporate actions. For investors, this suggests that while the company's operational framework is stable, the analytical narrative surrounding its market position and future outlook has been materially downgraded, warranting a closer examination of the revised key takeaways and business summary.

Analysts project 2,867% upside to a $20 target price, signaling strong potential for significant valuation re-rating.

The company maintains a debt-to-equity ratio of 0.04, placing it in the top quartile for leverage safety.

A current ratio of 25.97 indicates robust short-term liquidity, effectively mitigating immediate solvency concerns for the firm.

Revenue grew at a 10.6% CAGR from FY2023 to FY2025, demonstrating consistent top-line expansion over the period.

Cash conversion metrics rank above the cohort median, suggesting relatively efficient management of operating cash flows.

The company posted a net loss of nearly $6 million in FY2025, reflecting persistent and deepening operational unprofitability.

Operating margins of -1,024% place the firm in the bottom quartile, indicating severe inefficiency compared to peers.

Medium dilution risk flags potential equity issuance, which could erode existing shareholder value and ownership stakes.

Revenue $0.00; Operating income -$1.5M.

• ▍Revenue $0.00
• ▍Operating income -$1.5M

Revenue $3.0k; Operating income -$4.2M.

• ▍Revenue $3.0k
• ▍Operating income -$4.2M
• ▍Net margin -136911.1%

Revenue $3.0k; Operating income -$2.9M.

• ▍Revenue $3.0k
• ▍Operating income -$2.9M
• ▍Net margin -95713.3%

Revenue $6.0k; Operating income -$6.1M.

• ▍Revenue $6.0k
• ▍Operating income -$6.1M
• ▍Net margin -99916.8%

Revenue $11.0k; Operating income -$5.7M.

• ▍Revenue $11.0k
• ▍Operating income -$5.7M
• ▍Net margin -49940.7%

Revenue $11.0k; Operating income -$5.7M.

• ▍Revenue $11.0k
• ▍Operating income -$5.7M
• ▍Net margin -49940.7%

Revenue $9.0k; Operating income -$5.6M.

• ▍Revenue $9.0k
• ▍Operating income -$5.6M
• ▍Net margin -58739.7%

Revenue $9.0k; Operating income -$5.6M.

• ▍Revenue $9.0k
• ▍Operating income -$5.6M
• ▍Net margin -58739.7%